Causes of death after hip fracture in senile patients / 中华创伤杂志(英文版)

Hip trauma has been a leading cause of death in senile patients for more than a centenary. Although the mortality decreased due to the advanced technique in medication, surgery and nursing, the increasing mortality should not be neglected in elders after orthopedic operation nowadays. Many factors are considered to influence the causes of death after trauma, such as age, gender, personal customs, comorbidities, types of fracture, timing of surgery, procedure, anesthesia, complications, medical treatment, activity of daily living, or even marriage status. This article reviews these causes from the aspects of patient's own factors, iatrogenic factors, medical treatment and other factors and provides some clues for further clinical application according to the recent foreign and domestic researches. According to the present research, it is essential for surgeons to perform a comprehensive estimation for patients suffering from hip trauma.

Inhibitory effect of extrinsic CO-releasing molecules-2 (CORM-2) on inflammatory responses in mice with LPS-induced acute lung injury / 浙江大学学报·医学版

<p><b>OBJECTIVE</b>To investigate the effects of extrinsic CO-releasing molecules-2 (CORM-2) on attenuating pulmonary injury and the inflammatory response in LPS-induced acute lung injury of mice.</p><p><b>METHODS</b>Fifty-three mice were assigned to four groups. Mice in sham group (n= 8) underwent sham inhalation, whereas mice in ALI (n= 15) received inhalation of LPS for 30 min, mice in ALI+iCORM (n= 15) underwent LPS inhalation with immediate administration of inactive CORM-2 (8 mg/kg, i.v.), mice in ALI+CORM (n= 15) underwent LPS inhalation with immediate administration of CORM-2 (8 mg/kg, i.v.). PMN accumulation (MPO assay) in mice lungs and TNF-α and IL-1 β in BAL fluid were determined. Activation of NF-kB and expression level of ICAM-1 in the lung were assessed.</p><p><b>RESULT</b>Treatment of ALI mice with CORM-2 attenuated PMN accumulation and prevented activation of NF-kB in the lung. This was accompanied by a decrease of the expression of ICAM-1. In parallel, CORM-2 markedly decreased the production of inflammatory mediators in BAL fluid.</p><p><b>CONCLUSION</b>CORM-2 attenuates the inflammatory response in the lung of LPS-induced ALI by decreasing leukocyte sequestration and interfering with NF-kB activation, expression of ICAM-1 and therefore suppressing endothelial cells pro-adhesive phenotype.</p>

Application of Aidi injection (艾迪注射液) in the bronchial artery infused neo-adjuvant chemotherapy for stage III A non-small cell lung cancer before surgical operation / 中国结合医学杂志

<p><b>OBJECTIVE</b>To study the effect of Aidi Injection (艾迪注射液,ADI) applied in the bronchial artery, applied in the bronchial artery infused (BAI) neo-adjuvant chemotherapy for stage III A non-small cell lung cancer (NSCLC) before surgical operation.</p><p><b>METHODS</b>The 60 patients with NSCLC stage III A underwent two courses BAI chemotherapy before tumor incision were assigned to two groups, the treatment and the control groups, using a random number table, 30 in each group. ADI (100 mL) was given to the patients in the treatment group by adding into 500 mL of 5% glucose injection for intravenous dripping once daily, starting from 3 days before each course of chemotherapy, and it lasted for 14 successive days, so a total of 28 days of administration was completed. The therapeutic effectiveness and the adverse reaction that occurred were observed, and the levels of T-lymphocyte subsets, natural killer cell activity, and interleukin-2 in peripheral blood were measured before and after the treatment.</p><p><b>RESULTS</b>The effective rate in the treatment group was higher than that in the control group (70.0% vs. 56.7%, P<0.05). Moreover, as compared with the control group, the adverse reaction that occurred in the treatment group was less and mild, especially in terms of bone marrow suppression and liver function damage (P<0.05). Cellular immune function was suppressed in NSCLC patients, but after treatment, it ameliorated significantly in the treatment group, showing significant difference as compared with that in the control group (P<0.05).</p><p><b>CONCLUSION</b>ADI was an ideal auxiliary drug for the patients in stage III A NSCLC received BAI neo-chemotherapy before surgical operation; it could enhance the effectiveness of chemotherapy, ameliorate the adverse reaction and elevate patients' cellular immune function; therefore, it is worthy for spreading in clinical practice.</p>